Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Which Stock Should You Track
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Market
Dr Lal PathLabs PE 58.71, mkt cap Rs 32,077 crore. Metropolis Healthcare PE 60.47, mkt cap Rs 12,268 crore. Thyrocare Technologies PE 52.23, mkt cap Rs 9,186 crore.
Quick Answer
Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies is a side-by-side comparison of three companies from the Diagnostics space. On this comparison, Dr Lal PathLabs carries a market capitalisation of about Rs 32,077 crore against Rs 12,268 crore for Metropolis Healthcare and Rs 9,186 crore for Thyrocare Technologies, with return on equity of 20.13%, 12.56% and 27.85% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies starts with the core numbers most investors compare within the Diagnostics segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Diagnostics bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies: Company Overview
Dr Lal PathLabs is a listed Indian company in the Diagnostics space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Metropolis Healthcare is a listed Indian company in the Diagnostics space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Thyrocare Technologies is a listed Indian company in the Diagnostics space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Valuation and Profitability Snapshot
| Metric | Dr Lal PathLabs | Metropolis Healthcare | Thyrocare Technologies |
|---|---|---|---|
| Market Cap (approx.) | Rs 32,077 crore | Rs 12,268 crore | Rs 9,186 crore |
| PE Ratio (TTM) | 58.71 | 60.47 | 52.23 |
| PB Ratio | 12.79 | 8.17 | 17.92 |
| Return on Equity (ROE) | 20.13% | 12.56% | 27.85% |
| EPS (TTM, Rs) | 32.55 | 9.78 | 11.05 |
| Dividend Yield | 1.07% | 0.85% | 2.43% |
| Debt to Equity | 0.08 | 0.15 | 0.09 |
| Book Value per Share (Rs) | 149.45 | 72.41 | 32.21 |
Check the Univest Screener for Live Data
On valuation, Dr Lal PathLabs trades at a PE of 58.71 and a PB of 12.79, Metropolis Healthcare at a PE of 60.47 and a PB of 8.17, while Thyrocare Technologies trades at a PE of 52.23 and a PB of 17.92. On return on equity, the three post 20.13%, 12.56% and 27.85% respectively, and on dividend yield they stand at 1.07%, 0.85% and 2.43%.
Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Dr Lal PathLabs | Rs 829.60 crore | Rs 170.50 crore | +18.9% | +14.2% |
| Metropolis Healthcare | Rs 455.32 crore | Rs 56.88 crore | +15.7% | +5.2% |
| Thyrocare Technologies | Rs 244.17 crore | Rs 51.33 crore | +23.5% | +7.0% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three diagnostics names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies highlights how differently three companies in the same diagnostics segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies
What is the market cap difference between Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?
Ans. As of September 2026, Dr Lal PathLabs has a market cap of approximately Rs 32,077 crore, Metropolis Healthcare is at approximately Rs 12,268 crore, and Thyrocare Technologies is at approximately Rs 9,186 crore.
Which of the three has the highest PE ratio?
Ans. Among Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies, the PE ratios stand at 58.71, 60.47 and 52.23 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies post ROE of 20.13%, 12.56% and 27.85% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies carry dividend yields of 1.07%, 0.85% and 2.43% respectively.
What is the debt to equity ratio for Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?
Ans. Dr Lal PathLabs carries a debt to equity of 0.08, Metropolis Healthcare of 0.15, and Thyrocare Technologies of 0.09.
Which of the three trades at the highest price to book value?
Ans. Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies trade at price to book ratios of 12.79, 8.17 and 17.92 respectively.
Is one of Dr Lal PathLabs, Metropolis Healthcare or Thyrocare Technologies better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
